Industry
Biotechnology
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Loading...
Open
1.50
Mkt cap
122M
Volume
325K
High
1.51
P/E Ratio
-0.79
52-wk high
5.51
Low
1.42
Div yield
N/A
52-wk low
1.14
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
April 12, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 10:38 am
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 1:10 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 11:37 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.